Skip to main content
. Author manuscript; available in PMC: 2017 Jul 31.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2016 Jan 22;25(4):363–371. doi: 10.1002/pds.3959

Table 4.

Main and sensitivity analyses of benefit-harm metrics at different time points after randomization

Benefit-harm
metric
95% confidence
interval*
Probability of the
metric being
positive*
Main analysis
6 months −129 −242 to −14 1%
12 months −317 −436 to −196 0%
18 months −390 −514 to −264 0%
24 months −526 −687 to −368 0%
Sensitivity analysis one
6 months −201 −362 to −39 1%
12 months −482 −665 to −298 0%
18 months −603 −800 to −412 0%
24 months −808 −1049 to −570 0%
Sensitivity analysis two
6 months −115 −245 to 13 4%
12 months −292 −421 to −161 0%
18 months −339 −467 to −209 0%
24 months −439 −588 to −294 0%
*

95% confidence interval and the probability of the metric being positive were calculated based on the 10000 bootstrapping replicates.